Merck and Partner Ridgeback Fill U.S. Order for Covid-19 Pill
- Omicron wave spurred high demand for more treatment options
- Molnupiravir has so far been shipped to more than 25 countries
Merck & Co. and Ridgeback Biotherapeutics LP’s Molnupiravir antiviral medication.
Photographer: Kobi Wolf/BloombergThis article is for subscribers only.
Merck & Co. said that it had provided about 3.1 million courses of its Covid-19 pill to the U.S. government, fulfilling the terms of a federal pact that the drugmaker and partner Ridgeback Biotherapeutics LP agreed to last year.
The companies said in a statement on Tuesday that they have completed manufacturing of 10 million courses of the therapy and are on track to make at least 20 million courses this year.